Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Mcall

Published November 12, 2026 · Updated November 13, 2026

Trump administration will fund new research on controversial psychedelic drug ibogaine

Read the full story at Mcall

Federal officials on Thursday announced new funding to explore the medical potential of ibogaine, a controversial psychedelic drug ... Crime & Public.

Surfaced by 10 Google Alerts

  • Psychedelic crime
  • Psychedelic press release
  • LSD
  • Psychedelics africa
  • Ibogaine
  • Psychedelics europe
  • Psychedelics south america
  • Psychedelics middle east
  • Psychedelic biotech
  • Psychedelics